Aug., 08th, 2015, Mumbai, India: Market Reports on China presents the report “Market research and Investigation Report on China Ossotide Market, 2010-2019”. This research reports provide the Patients with osteoarthritis typically show reduced mobility and life quality caused by joint pain.
According to statistics, the incidence of rheumatoid arthritis (RA) is 0.2%-0.36% and the number of cases is 5-10 million in China. Apart from RA, osteoarthritis, an expression of degraded joint function, is also common to see. (http://www.marketreportsonchina.com/life-sciences-market-research-reports-16462/investigation-china-ossotide.html) With the ageing population in China, over 60% of elder people aged above 60 suffer from osteoarthritis, says a study. Patients with osteoarthritis typically show reduced mobility and life quality caused by joint pain, malformation and joint dysfunction.
Ossotide can not only regulate bone metabolism, stimulate osteoblast proliferation, accelerate new bone formation but also regulate calcium-phosphorus metabolism, increase calcium deposits so as to prevent osteoporosis. Ossotide injection and compound ossotide injection was first developed by Nanjing Xinbai Pharmaceutical Co., Ltd which was formerly Nanjing Biochemical Pharmaceutical Factory.
In recent years, compound ossotide injection market has shown increasingly fierce competition as it is going from short supply to oversupply, from huge profits to meager profit. Besides, the rise in raw material price has stressed the profit margins.
After entering China market, ossotide is generally growing despite a decline in 2013 with annual sales value rising from less than CNY 60 million in 2005 to CNY 464 million in 2014 and CAGR during this period reaching over 26%. According to CRI-s market survey, ossotide in the Chinese market mainly come from Harbin Medisan Pharmaceutical Co., Ltd, ZBD Pharmaceutical, Heilongjiang Jiangshi Pharmaceutical Co., Ltd, among which Harbin Medisan Pharmaceutical Co., Ltd has the largest market share of about 19% for sales value in 2014.
The market size of ossotide is expected to keep growing in the next few years in China.
Readers can get at least the following information from this report:- market size of ossotide in China
- competitive landscape of ossotide in Chinese market
- price of ossotide made by different enterprises in China
- market outlook of ossotide in China
The author suggests the following groups of people purchase this report:- manufacturers of drugs for bones and muscles
- investors/ research institutions interested in Chinese medicine market
- any interest in the Chinese medicine market, please contact CRI for customized survey service
1 Related Concepts of Ossotide1.1 Indication
1.2 Sales Status in Global Market
2 Market Profile of Ossotide in China2.1 Patent and Approval Status of Ossotide in China
2.2 Major Manufacturers
2.3 Market Size
3 Survey on Sales Status of Ossotide in China, 2010-20143.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 Survey on Market Share of Major Manufacturers of Ossotide in China, 2010-20144.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
To view a full Executive Summary and Table of Contents, please visit: http://www.marketreportsonchina.com/life-sciences-market-research-reports-16462/investigation-china-ossotide.html
About Author Bio: Sarah Davis is working with MarketReportsonChina which is a portal where you can access thousands of reports on China starting from Aeronautics to Zinc (A-Z). The website provides market reports on different sectors like